Clinical Core People
Bonnie Ramsey, MD, Program
Director and Director, Clinical Core - http://depts.washington.edu/pedspulm/bioramsey.htm
Dr.
Ramsey has been a clinical investigator in the field of cystic fibrosis
(CF) for over 25 years. She is the co-PI of the Clinical Translational
Science Award at the University of Washington, Vice Chair for Research
of the Department of Pediatrics, and Director of the Coordinating
Center of the Cystic Fibrosis Therapeutics Development Network, a
clinical trials network composed of 77 research sites throughout the
US. She is a Professor of Pediatrics holding an Endowed Chair in Cystic
Fibrosis Research. She is an elected Fellow of the American Pediatric
Society and the American Association of Physicians. Dr. Ramsey along
with Dr. E. Peter Greenberg will oversee all administrative and
scientific aspects of the center. In addition, Dr. Ramsey is the
Director for the Clinical Core of the Seattle CFRTC. She is an
internationally recognized leader in clinical research in cystic
fibrosis. Her early research was instrumental in moving inhaled
tobramycin solution from early translational studies to eventual FDA
approval in the United States. She also launched the CFF TDN in
conjunction with the CF Foundation in 1998 and has successfully
overseen the network's rapid growth and development.
Christopher H. Goss, MD MSc (http://depts.washington.edu/pulmcc/directory/bio/goss.html)
Dr.
Goss is an Associate Professor of Medicine in the Division of Pulmonary
and Critical Care Medicine and an Adjunct Associate Professor of
Pediatrics. He will serve as the co-Director of the Clinical
Translational Core of the P30. He is the Chief Medical Officer of the
CFF TDNCC and has over 10 years of experience in clinical trials in CF.
He received his MSc in Epidemiology from the University of Washington
in 2000 and is an expert in clinical trial design and clinical trial
outcome measures with an emphasis on patient reported outcomes. He has
served as Chair of the Cystic Fibrosis Foundation Registry Committee
for the last 6 years. He is co-director of the Clinical Research
Training Track for the Pulmonary Division at the University of
Washington.
Ronald L. Gibson,
MD PhD. (http://depts.washington.edu/pedspulm/biogibson.htm)
Dr.
Gibson is a Professor of Pediatrics in the Division of Pulmonary
Medicine. Dr. Gibson has prior basic research experience in
microbiology, and his current clinical research is directed at cystic
fibrosis (CF) lung disease, with a focus on risk factors for and
treatment of early Pseudomonas aeruginosa airway infection. He is the
co-principal investigator for a large-scale investigation of risk
factors for early and chronic infection with Pseudomonas aeruginosa,
and a co-investigator on an NIH-funded study to evaluate genetic
modifiers of early CF lung disease. Dr. Gibson is the Director of the
Clinical Core of the CF Research Development Program at the UW that
fosters local, CF-related clinical and translational research. He is
also the co-principal investigator of the CFF TDN Center at the UW, the
CF Center Director at Seattle Children's Hospital (SCH), and the
Steering Committee for the Center for Clinical and Translational
Research at SCH.
Margaret
Rosenfeld, MD MPH. (http://depts.washington.edu/pedspulm/biorosenfeld.htm)
Dr.
Rosenfeld is an Associate Professor of Pediatrics in the Division of
Pulmonary Medicine. Her research program focuses on the assessment and
treatment of early CF lung disease, including the development of
appropriate outcome measures (infant and preschool lung function
tests), clinical trials of hypertonic saline in young children with CF,
and a large-scale investigation of risk factors for early acquisition
of Pseudomonas aeruginosa. She also conducts research in defining a CF
pulmonary exacerbation and choosing appropriate pulmonary function
reference equations. She is Associate Director of the Seattle
Children's Hospital Center for Clinical and Translational Research. She
chaired the task force responsible for implementing CF newborn
screening in Washington State and serves as CF Consultant to the
Washington State Newborn Screening Lab. She is the co-Chair of the CFF
TDN group on outcome measures in infant and young
children.
Sonya Heltshe, PhD.
Dr. Heltshe received her PhD in biostatistics from the University of Colorado School of Public Health in 2007. She worked as a statistician with Children's Hospital Colorado Cystic Fibrosis Center from 2002 through 2007 while completing her doctoral work. There, she collaborated on research of CF lung function, microbial diversity, proteomics, and inflammatory markers. Dr. Heltshe received a training fellowship through the National Cancer Institute in 2007 and completed a year long post-doc with the Biometrics Branch of the Division of Cancer Epidemiology and Genetics. In 2009 she came to the CF Foundation's Therapeutic Development Network (TDN) Coordinating Center in Seattle, WA as a senior biostatistician. She has devoted an extensive effort to CF newborn growth endpoints and standards with a continued commitment to biomarkers and nutritional facets in the CF population. She is currently an Assistant Professor of Research in the Department of Pediatrics at University of Washington.
Denny Liggitt, DVM, PhD. (https://www.iths.org/PRDC/DDAC/members )
Dr. Liggitt is a Professor and Chairman
of the Department of Comparative Medicine, School of Medicine,
University of Washington (UW). Dr. Liggitt is a board-certified
comparative pathologist who also serves as an advisor to the UW ITHS
Preclinical Research Development Network (PRDN) as well as the Cystic
Fibrosis Foundation and others. Dr. Liggitt is an authority in the
development and evaluation of models of human diseases and has
published more than 150 scientific papers in this and related areas. He
has particular expertise in the use of these models and associated
systems for the preclinical development, safety/toxicity evaluation,
and approval of biologic-based drugs. He was formerly an Associate
Director of Pharmacology at Genentech Inc. and when there established
the preclinical pathology section. Dr. Liggitt will provide a key link
between the preclinical consultation in this group and the Comparative
Pathology group in the Inflammation Core.
